Related Experiment Video
Updated: Feb 17, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
CDK4 expression in chordoma: A potential therapeutic target
Tang Liu1,2, Jacson K Shen1, Edwin Choy1
1UCLA Orthopaedic Surgery, Sarcoma Biology Laboratory, 615 Charles E Young Dr. South, Biomedical Sciences Research Building, Room 410, Los Angeles, CA 90095.
Targeting cyclin-dependent kinase 4 (CDK4) shows promise for chordoma treatment. High CDK4 expression in chordoma tissues correlates with metastasis and recurrence, and inhibiting it slows tumor growth.
Area of Science:
- Orthopaedic Oncology
- Cancer Biology
- Molecular Therapeutics
Background:
- Chordomas are rare bone tumors lacking standard chemotherapy.
- Current treatments rely on surgery and radiotherapy.
- Understanding molecular targets is crucial for novel therapies.
Purpose of the Study:
- To investigate cyclin-dependent kinase 4 (CDK4) expression in chordoma.
- To explore the functional role of CDK4 in chordoma cell growth and proliferation.
- To evaluate the therapeutic potential of targeting CDK4 in chordoma.
Main Methods:
- CDK4 expression analysis in chordoma cell lines and patient tissues.
- Functional studies on CDK4's role in cell growth and proliferation.
- In vitro treatment with CDK4 inhibitor palbociclib.
Main Results:
- CDK4 was highly expressed in chordoma cell lines and 97.7% of tissues.
- Elevated CDK4 expression correlated with chordoma metastasis and recurrence.
- Palbociclib treatment significantly inhibited chordoma cell growth and proliferation.
Conclusions:
- CDK4 is a highly expressed protein in chordoma.
- Targeting CDK4 represents a potential novel therapeutic strategy for chordoma.
- CDK4 inhibition may offer a new treatment avenue for chordoma patients.
More Related Videos
10:09Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
Related Concept Videos
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Positive Regulator Molecules
Mitogens and the Cell Cycle
Abnormal Proliferation